A novel hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent.

In addition to the poster on AEZS-108, the Company may also present posters on preclinical results for three of its various other novel anticancer compounds:.. Aeterna Zentaris to present AEZS-108 Phase 2 results for endometrial cancer at EORTC-NCI-AACR Symposium Aeterna Zentaris Inc. AEZS-108, a novel hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin, is definitely in a Phase 2 trial in advanced endometrial.Endovascular repair is just about the treatment modality of preference for most patients with aneurysms above a threshold size. Abdominal aortic aneurysms predominantly affect males aged over 65 years, with a prevalence of 10 percent in guys aged over 80 years. AAA may be the third many common reason behind sudden death in older men, after myocardial stroke and infarction. Most AAAs are asymptomatic and so are incidentally diagnosed.